O
The startup develops oncology treatments that enhance T-cell migration and activity in resistant tumor sites, specifically targeting CCR8-expressing regulatory T cells to improve anti-tumor immune responses. Their focus on orphan pediatric oncology aims to provide new therapeutic options through preclinical research and drug development programs.
Leuven, Belgium
Updated 2 months ago
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops oncology treatments that enhance T-cell migration and activity in resistant tumor sites, specifically targeting CCR8-expressing regulatory T cells to improve anti-tumor immune responses. Their focus on orphan pediatric oncology aims to provide new therapeutic options through preclinical research and drug development programs.